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Abstract
Background
It is well established that the idle peripheral intravenous catheter (PIVC) provides no thera-
peutic value and is a clinical, economic and above all, patient concern. This study aimed to
develop a decision aid to assist with clinical decision making to promote clinically indicated
peripheral intravenous catheter (CIPIVC) insertion in the emergency department (ED) set-
ting. Providing evidence for a uniform process could assist clinicians in a decision-making
process for PIVC insertion. This could enable patients receive appropriate vascular access
healthcare.
Methods
We performed a secondary analysis of data from a multicentre cohort of emergency depart-
ment clinicians who performed PIVC insertion. We defined CIPIVC a priori as one used for a
specific clinical treatment and or procedure such as prescribed intravenous (IV) fluids; pre-
scribed IV medication; or IV contrast (for computerized tomography scans). We sought to
refute or validate an assumption if the clinician performing or requesting the insertion
decided the patient was >80% likely to need a PIVC. Using logistic regression, we derived a
decision aid for CIPIVCs.
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Results
In 817 patients undergoing PIVC insertion, we observed 68% of these to be CIPIVCs. Admit-
ted patients were significantly more likely to have a CIPIVC, Odds Ratio (OR) = 3.05, 95%
confidence interval (CI) = 2.17–4.30, p = <0.0001. Before insertion, patients who definitely
needed IV fluids/medicines OR = 3.30, 95% CI = 2.02–5.39, p = <0.0001 and who definitely
needed a contrast scan OR = 3.04, 95% CI = 1.15–8.03, p = 0.0250 were significantly more
likely to have a device inserted for a clinical indication. Patients who presented with an exist-
ing vascular access device were more likely to have a new CIPIVC inserted for use OR =
4.35, 95% CI = 1.58–11.95, p = 0.0043. The clinician’s pre-procedural judgment of the likeli-
hood of therapeutic use >80% was independently associated with CIPIVC; OR 3.16, 95%
CI = 2.06–4.87, p<0.0001. The area under the receiver operating characteristic curve was
0.81, and at the best cut-off, the model had a specificity of 0.81, sensitivity of 0.71, a positive
predictive value of 0.89 and negative predictive value of 0.57.
Conclusions
Using the derived decision aid, clinicians could ask:- “Does this patient need A-PIVC?” Clini-
cians can decide to insert a CIPIVCs when: (i) Admission to hospital is anticipated and when
(ii) a Procedure requires a PIVC, e.g., computerised tomography scans and where an exist-
ing suitable vascular access device is not present and or; (iii) there is an indication for IV flu-
ids and or medicines that cannot be tolerated enterally and are suitable for dilution in
peripheral veins; and, (iv) the Clinician’s perceived likelihood of use is greater than 80%.
Introduction
The annals of vascular access history show that we have attempted to perform peripheral intra-
venous cannulation since 1492 [1]. In the centuries since, ethical principles such as beneficence
and non-maleficence underpinned by the concepts “first do no harm” or “first do no net
harm” have developed to substantiate part of a clinician’s clinical decision making [2]. The
peripheral intravenous catheter (PIVC), is the most prevalent of all vascular access devices and
is primarily initiated when intravenous fluids and or medication is prescribed, to relieve
patients of pain and/or assist patients to better health [3]. In contrast, the insertion of an
unnecessary PIVC challenges the concept of first do no harm [4]. Current evidence of unused
PIVC rates for patients admitted via the Emergency Department (ED) setting range from 25–
50% [5–7]. Additionally, avoiding inappropriate PIVC placement upholds the concept of ves-
sel health and preservation [8].
The revelation that up to half of all PIVCs inserted in the ED are unused is disturbing and
has prompted a closer examination of this clinical procedure [5]. Becerra and colleagues per-
formed an integrative review on the prevalence of idle PIVCs and called for stronger criteria
for clinically indicated peripheral intravenous catheter (CIPIVC) use [9]. The review demon-
strated heterogeneous definitions of the idle PIVC (those not deemed to be a CIPIVC) and var-
ied from: the length of time (hours and days); in situ without infusion therapy; lack of
prescribed intravenous fluids or medicines; and even the unspecified descriptor of patient
instability [9]. More recently a specific ED review on idle PIVCs identifies a median prevalence
of idle PIVC to be 32.4% [10].
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At a minimum, refraining from inserting a PIVC that is not clinically indicated would
avoid pain, and reduce costs of staff and equipment resources involved. Besides, it would not
place the patient at risk of more serious complications such as vein injury and thrombophlebi-
tis. Blood sampling from PIVCs inserted in the ED is very common as it is thought to preserve
the patient’s vessel health and thus a repeated needle insertion is avoided. Unfortunately, it is
this sort of practice that contributes to an unnecessary insertion when the PIVC is used for
one-off blood sampling and not for intravenous fluids and or medication infusions. Thus, the
term the idle PIVC is coined. Furthermore, the ED inserted PIVC that remains intravenous
without a clinical indication contributes to hospital-acquired infection risk including staphylo-
coccus aureus bloodstream infections [11]. Therefore, given the morbidity and cost associated
with catheter-related infections, better clinical decision aids to avoid unnecessary PIVCs in the
first place may address clinical and economic concerns.
The process of describing PIVC use is best understood when separated into three distinct
phases: pre-insertion; insertion; and post insertion. Focusing on the pre-insertion phase (as
this paper does) and developing a uniform set of criteria for CIPIVC insertion, facilitates the
reduction of unnecessary PIVC attempts. Proper attention paid to this phase will avoid the
insertion of “just in case” PIVCs. The PIVC is an invasive device that comes with a variety of
risks and it should be dependent upon a well-defined clinical rationale for insertion to proceed.
Patients, must, where possible, be made aware of these risks. This study intended to improve
the quality of clinical practice with vascular access in the ED and specifically, to describe fac-
tors associated with the clinical indication for a PIVC insertion [12]. Given the fact that PIVC
assessment tools have shown questionable clinical reliability and PIVC removal is poorly
recorded in the medical record [13,14] better strategies are needed to improve data capture
and perhaps identify why PIVCs are clinically justified is a good start.
Methods
Study aim
We aimed to identify factors associated with CIPIVC status so that we could develop a clinical
decision aid for CIPIVC insertion to facilitate decision-making and reduce unnecessary
PIVCs.
Study design, setting, sampling and participants
We performed secondary data analysis on a dataset regarding of PIVC insertion outcomes in
the ED setting [12] which was registered as a clinical trial with the Australian and New Zealand
Trials Registry (ANZCTRN12615000588594). The study setting included two large academic
affiliated institutions in Perth, Western Australia. The first is a 650-bed hospital treating
approximately 65,000 patients present annually in the ED. The other is a 783-bed hospital with
approximately 80,000 adult ED presentations [12]. The dataset was developed using a conve-
nience sampling method due to limited funding and included all patients with various Austral-
asian Triage Scale (ATS) 1–5, who received a PIVC.
Study definitions
For this study and analysis, we defined CIPIVCs that were used for a: (i) clinical procedure
requiring intravenous contrast or medicines; (ii) prescribed IV fluids and or IV medication
(IVFM) in the ED or during admission to hospital.
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Data collection
We collected data from June 2015 to May 2016 using a case report form that we had developed
prior to the main study and was assessed as having an item content validity index score of
greater than 0.78, suggesting good content validity [15]. Two research assistants separately
gathered observation data on PIVC insertion and followed up those admitted to hospital for
use until removal. Follow up data included patient, clinician, and product factors. Before inser-
tion, the inserting clinician was asked how likely the PIVC would be needed for clinical use on
a scale of 0% = not likely to be needed, to 100% = extremely likely to be needed.
Additionally, clinicians were asked if the purpose was for blood sampling and if intravenous
fluids; medicines; and contrast scan would be definitely or possibly prescribed. We then fol-
lowed up the patients to see if fluids and or medicines were prescribed and administered. A
sample of data from each was assessed initially and obtained high-reliability scores. Kappa was
above 0.90 suggesting a very high level of agreement [16].
Data analysis
Summary statistics are provided for all variables of interest, including means and standard
deviations (SD) for continuous variables as well as counts (N) and percentages (%) for each of
the categorical variables. Predictors of CIPIVC insertion were identified using univariate and
multivariate logistic regression to investigate variables related to whether the PIVC was clini-
cally indicated (event = “PIVC clinically indicated”). Backwards model selection was used
where variables significant at the 5% level were retained for the final multivariate model.
Adjusted odds ratios (OR), 95% confidence intervals (CI), and P-values are provided. Data
were analysed using the R environment for statistical computing [17].
Ethics: Approvals for this study were obtained from The Sir Charles Gairdner Hospital
(SCGH) Human Research Ethics office ref: HR 2015–149 with reciprocated approval gained at
Fiona Stanley Hospital and Griffith University. We observed only clinicians who, after an invi-
tation to contribute to the study, provided consent. A waiver of consent was granted to allow
us observe patients receiving PIVCs. We used the STROBE statement to report our findings.
Results
Table 1 displays patient characteristics for the 817 patients with observed PIVC insertions
including those that were CIPIVCs (n = 553; 67.7%) and those that were not CIPIVCs
(n = 264; 32.3%). There were more female patients n = 431 (53%) represented, and the mean
age was 60 (SD 22) years. The most common triage category was ATS 3 (n = 339; 42%), fol-
lowed by ATS 2 (n = 277; 34%). The professional designation of those who performed the
most PIVC insertions was the resident medical officer (RMO; n = 343; 42%), with 385 (47%)
clinicians having inserted more than 1000 PIVCs in their career. PIVCs were inserted for the
initial purpose of obtaining a blood sample in 748 (92%) patients, with 292 (36%) not having
any IV fluids, IV medication infused. Four-hundred and five (84%) patients with a pre-inser-
tion likelihood of use of greater than 80%, received CIPIVC, whereas 148 (44%) of patients
with a pre-insertion clinician-estimated likelihood of use less than 80% received a CIPIVC.
Regression results
Table 2 displays the univariate and multivariate results from analyzing whether a PIVC inser-
tion was clinically indicated as per the definition, while Fig 1 displays the receiving operating
characteristic curve produced by the final multivariate model. Those with blood sampling
obtained were less likely to require CIPIVC insertion (univariate OR = 0.46, 95% CI = 0.25–
Derivation of A-PIVC decision aid
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Table 1. Overall patient characteristics and by CIPIVC insertion classification.
CIPIVC Insertion Overall (N = 817)
Yes (N = 553; 67.7%) No (N = 264; 32.3%)
Patient Gender
Male 270 (70.0%) 116 (30.0%) 386 (47.3%)
Female 283 (65.7%) 148 (34.3%) 431 (52.7%)
Patient Age
Years (Mean, SD) 59.8 (22.6) 60.8 (22.0) 60.1 (22.4)
Triage Category
1 - 32 (82.1%) 7 (17.9%) 39 (4.8%)
2 - 185 (66.78%) 92 (33.2%) 277 (33.9%)
3 - 236 (69.6%) 103 (30.4%) 339 (41.5%)
4 - 97 (61.8%) 60 (38.2%) 157 (19.2%)
5 - 3 (60.0%) 2 (40.0%) 5 (0.6%)
Staff Role
Nurse 44 (58.7%) 31 (41.3%) 75 (9.2%)
Med Student 29 (69.1%) 13 (30.9%) 42 (5.1%)
Intern 57 (63.3%) 33 (36.7%) 90 (11.0%)
RMO 225 (65.6%) 118 (34.4%) 343 (42.0%)
Registrar 93 (69.4%) 41 (30.6%) 134 (16.4%)
Consultant 44 (80.0%) 11 (20.0%) 55 (6.7%)
US Consultant 12 (92.3%) 1 (7.7%) 13 (1.6%)
Phlebotomist 49 (75.4%) 16 (24.6%) 65 (8.0%)
Staff Experience
<10 3 (50.0%) 3 (50.0%) 6 (0.7%)
11–50 31 (66.0%) 16 (34.0%) 47 (5.8%)
51–100 30 (60.0%) 20 (40.0%) 50 (6.1%)
101–300 71 (69.6%) 31 (30.4%) 102 (12.5%)
301–600 60 (61.9%) 37 (38.1%) 97 (11.9%)
601–1000 85 (65.4%) 45 (34.6%) 130 (15.9%)
>1000 273 (70.9%) 112 (29.1%) 385 (47.1%)
Patient Admitted
Yes 371 (78.4%) 102 (21.6%) 473 (57.9%)
No 182 (52.9%) 162 (47.1%) 344 (42.1%)
Existing Device
Yes 50 (90.9%) 5 (9.1%) 55 (6.7%)
No 503 (66.0%) 259 (34.0%) 762 (93.3%)
Blood Samples
Yes 497 (66.4%) 251 (33.6%) 748 (91.56%)
No 56 (81.2%) 13 (18.8%) 69 (8.4%)
Possible IVT
Yes 152 (54.7%) 126 (45.3%) 278 (34.0%)
No 401 (74.4%) 138 (25.6%) 539 (66.0%)
Definite IVT
Yes 307 (88.5%) 40 (11.5%) 347 (42.5%)
No 246 (52.3%) 224 (47.7%) 470 (57.5%)
IVT Infused
Yes 525 (100%) 0 (0.00%) 525 (64.3%)
No 28 (9.59%) 264 (90.4%) 292 (35.7%)
(Continued)
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0.86) but this was not significant in the multivariate analysis. Nurses were the most likely to
insert an unused PIVC; however, this relationship did not reach statistical significance. Fur-
thermore, no statistically significant associations between requiring a CIPIVC and patient
age, patient gender, and staff experience were observed. The final multivariate model found
five independent factors associated with CIPVC insertion; (i) admitted patients were more
likely to receive a CIPIVC (OR = 3.05, 95% CI = 2.17–4.30, p = <0.0001); (ii) patients with
an existing device were significantly more likely to require a CIPIVC (OR = 4.35, 95%
CI = 1.58–11.95, p = 0.0043); (iii) patients predicted by clinicians as definitely needing IVT
prior to insertion were significantly more likely to require a CIPIVC than patients who were
not (OR = 3.30, 95% CI = 2.02–5.39 p = <0.0001); (iv) patients predicted to definitely need
a contrast scan were significantly more likely to require a CIPIVC (OR = 3.04, 95%
CI = 1.15–8.03, p = 0.0250); and (v) patients predicted pre-procedurally to have >80% like-
lihood of use were significantly more likely to require a CIPIVC (OR 3.16, 95% CI = 2.06–
4.87, p<0.0001).
Fig 1 displays the area under the receiver operating characteristic curve of the final mul-
tivariate model which was 0.81, and at the best cut-off the model yielded a specificity of
0.81, sensitivity of 0.71 a positive predictive value of 0.89 and negative predictive value of
0.57.
Table 1. (Continued)
CIPIVC Insertion Overall (N = 817)
Yes (N = 553; 67.7%) No (N = 264; 32.3%)
Possible Contrast
Yes 26 (56.5%) 20 (43.5%) 46 (5.6%)
No 527 (68.4%) 244 (31.6%) 771 (94.4%)
Definite Contrast
Yes 25 (80.7%) 6 (19.35%) 31 (3.8%)
No 528 (67.2%) 258 (32.82%) 786 (96.2%)
CT Scan
No CT Scans 368 (62.6%) 220 (37.4%) 588 (72.0%)
CT Non-Contrast 69 (61.1%) 44 (38.9%) 113 (13.8%)
CT +Contrast 116 (100%) 0 (0.00%) 116 (14.2%)
Blood Products
Yes 9 (64.3%) 5 (35.7%) 14 (1.7%)
No 544 (67.8%) 259 (32.3%) 803 (98.3%)
Code Black
Yes 12 (80.0%) 3 (20.0%) 15 (1.8%)
No 541 (67.5%) 261 (32.5%) 802 (98.2%)
Patient Unstable
Yes 82 (78.1%) 23 (21.9%) 105 (12.9%)
No 471 (66.2%) 241 (33.8%) 712 (87.1%)
How Likely
�80% 148 (44.2%) 187 (55.8%) 335 (41.0%)
>80% 405 (84.0%) 77 (16.0%) 482 (59.0%)
Hospital
SCGH 322 (71.1%) 131 (28.9%) 453 (55.5%)
FSH 231 (63.5%) 133 (36.5%) 364 (44.5%)
Standard deviation SD; computerised tomography CT; Intravenous therapy IVT; Sir Chares Gairdner Hospital SCGH; Fiona Stanley Hospital FSH; Ultrasound US
https://doi.org/10.1371/journal.pone.0213923.t001
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Table 2. Univariate and multivariate logistic regression of whether the PIVC was used or not.
UNIVARIATE MULTIVARIATE
OR 95% CI OR 95% CI P-value
Patient Gender
Female vs. Male 0.82 0.61–1.10 Not Significant
Triage Category
1 vs. 5 3.05 0.43–21.79 Not Significant
2 vs. 5 1.34 0.22–8.16
3 vs. 5 1.53 0.25–9.28
4 vs. 5 1.08 0.18–6.64
Staff Role
�Consultant vs. Nurse 3.29 1.52–7.13 Not Significant
Intern vs. Nurse 1.22 0.65–2.28
Med Student vs. Nurse 1.57 0.71–3.50
Phlebotomist vs. Nurse 2.16 1.04–4.47
RMO vs. Nurse 1.34 0.81–2.24
Registrar vs. Nurse 1.60 0.89–2.88
Staff Experience
301–1000 vs. <301 0.92 0.62–1.36 Not Significant
>1000 vs. <301 1.26 0.88–1.82
Patient Admitted
Yes vs. No 3.24 2.39–4.39 3.05 2.17–4.30 <0.0001
Existing Device
Yes vs. No 5.15 2.03–13.07 4.35 1.58–11.95 0.0043
Blood Samples
Yes vs. No 0.46 0.25–0.86 Not Significant
Possible IVT predicted
Yes vs. No 0.42 0.31–0.56 Not Significant
Definite IVT predicted
Yes vs. No 6.99 4.80–10.18 3.30 2.02–5.39 <0.0001
Possible Contrast predicted
Yes vs. No 0.60 0.33–1.10 Not Significant
Definite Contrast predicted
Yes vs. No 2.04 0.83–5.03 3.04 1.15–8.03 0.0250
Blood Products
Yes vs. No 0.86 0.28–2.58 Not Significant
Code Black
Yes vs. No 1.93 0.54–6.90 Not Significant
Patient Age
For a One Year Increase 1.00 0.99–1.01 Not Significant
How Likely
>80% vs�80% 6.65 4.80–9.20 3.16 2.06–4.87 <0.0001
Deterioration/Patient Unstable
Yes vs. No 1.82 1.12–2.97 Not Significant
Hospital
FSH vs. SCGH 0.71 0.53–0.95 Not Significant
�Combined consultants and ultrasound accredited consultants.
Standard deviation SD; computerised tomography CT; Intravenous therapy IVT; Sir Chares Gairdner Hospital
SCGH; Fiona Stanley Hospital FSH, RMO Resident medical officer
https://doi.org/10.1371/journal.pone.0213923.t002
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Discussion
Our study shows that one-third of patients in two large Emergency Departments receive a
PIVC that is not clinically indicated based on our definition. This finding should raise both
clinical and economic concerns. We have identified five factors that are associated with
CIPIVC insertion and these can be used to guide decision making about whether to insert a
PIVC in the first place.
Admission to hospital was independently associated with CIPIVC inserted in ED. This
describes good practice for those that require it. However, the indiscriminate practice of PIVC
without a clinical indication is detrimental to good clinical care. If the clinician considers
Fig 1. Receiver operator characteristic curve of the final multivariate model.
https://doi.org/10.1371/journal.pone.0213923.g001
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discharge highly likely, the question of clinical indication for PIVC becomes even more perti-
nent. We identified that over 22% of the admitted cohort had a PIVC inserted with no intrave-
nous therapy, medication infused, and/or no CT contrast scan performed. Despite almost one
in three of all PIVCs having no clear indication or justification, it is unclear if these PIVCs
were all unjustified. At the time of insertion in ED, the clinician is likely focused on obtaining
PIVC for blood sampling and being cognizant of potential patient deterioration in an undiffer-
entiated patient and therefore, influencing the perception of what constitutes CIPIVC.
Additionally, the presence of an existing pre-hospital PIVC or patients with an existing vas-
cular access device (VAD) did not negate PIVC insertion, and this was statistically significant.
This emphasizes clinicians continue to rely on the PIVC as a reliable device to use despite post
insertion complications and high failure rates [18,19]. It is worthy of further investigation as to
why clinicians feel the need to instigate another PIVC rather than critically assess the utility of
the pre-hospital PIVC initiated elsewhere. Furthermore, as to why other existing devices such
as centrally terminating catheters were not used demands more investigation. Not all ED clini-
cians are familiar with using all vascular access devices. Regarding preserving vessel health,
perhaps the first consideration where possible and appropriate could be given to using the
existing device. Conversely, clinicians may feel ill-trained to manage such devices, are con-
cerns in case infection occurs or perhaps lack the necessary skills to do so, this is an issue cer-
tainly worthy of further inquiry. Furthermore, at a minimum and where practical, patient
input should be included given the growing appreciation of shared decision-making concept.
Significantly, prior to the insertion of a PIVC clinicians were able to predict the utility of
the device in terms of whether definitive intravenous therapy would be infused. In future it
may be worth assessing if any of these infusates could convert to an enteral prescription to
avoid PIVC insertion. Conversely, however, if the infusate is inappropriate for enteral pre-
scription but is likely to cause premature PIVC failure then selecting an appropriate device
may advantage both the patient and service provider [20]. Such a scenario would be dependent
on a system to resource point of care vascular access provision. Additionally, if definitive con-
trast CT scanning was predicted this was significantly related to a CIPIVC.
The final independent predictor in our analysis assesses the complexity of indications for
PIVC insertion, and we adopted a simple cut off percentage point of 80% for the anticipated
therapeutic use proposed by Kelly and Egerton-Warburton [21]. Encouragingly, this was
recently validated in a pre and post implementation study adopting are you 80% sure? as an
important predictor for a CIPIVC [22]. Our decision aid derived from a logistic regression
method suggests that clinician gestalt [23] represented by the clinician ability to predict PIVC
utility to be>80% represented an appropriate percentage for CIPIVC, thus providing further
evidence to support the concept of are you 80% sure? [22]. This is important given the call by
Becerra and colleagues for a uniform definition for the term ‘idle PIVC’ and as such is telling
of a system failure to understand or adequately rationalise any plausible clinical rationale for
patients receiving a PIVC [9].
No relationship was detected between the Australasian Triage Scale (ATS) and whether the
PIVC was clinically indicated in our multivariate analysis. However, this must be interpreted
cautiously as some ATS 1 (immediately life-threatening) and 2 (imminently life-threatening)
may have additional PIVCs inserted, as the anticipation of PIVC use is greatest in the ATS 1
and 2. For example, the ATS 1 with unused PIVCs in our dataset included patients with the
following presenting complaints and diagnoses which are at risk of acute deterioration: acute
stroke; acute shortness of breath with chronic airways disease; chest pain; arterial laceration;
code black/social presentation. All of which are likely contributing factors to a wide confidence
interval (CI) evidenced in the univariate analysis in Table 2.
Derivation of A-PIVC decision aid
PLOS ONE | https://doi.org/10.1371/journal.pone.0213923 March 22, 2019 9 / 14
There was a trend toward nurses being the professional group most likely to insert unused
PIVCs; however, it is not known if these were nurse-initiated decisions or a consequence of a
medical order or other (perceived) workflow processes. This is not a unique interpretation of
data regarding unused PIVCs as other reports revealing 50% rate of idle PIVCs identified that
nursing staff inserted 80% of the PIVCs [5]. This report also used a similar definition to our
CIPIVC. It accentuates the need for nurses to take a more involved role in decision-making
and as such could be improved with a decision aid. That said, more scientific and health ser-
vice enquiry should be carried out to identify why any clinical staff inserts PIVCs that are not
deemed clinically indicated.
A-PIVC decision aid
We present the A-PIVC decision aid which includes the following: admission to hospital;, with
the following circumstances; procedures requiring a PIVC e.g. computerised tomography
scans and where an existing device is not present; and or; indication for IV fluids and or medi-
cines that cannot be tolerated enterally and are suitable to for dilution in peripheral veins; cli-
nician likelihood of therapeutic use is greater than 80%, see a fuller explanation in S1 and S2
Figs. Although admitted patients were independently associated with CIPIVC, it is worth
emphasizing that CIPIVC can occur in the ED patient who does not get admitted. Addition-
ally, a PIVC might be the inappropriate vascular access device choice, and alternative devices
could be considered for admitted patients. Furthermore, patients sometimes are admitted for
supportive care and allied health input and do not require imaging or IV fluids and medica-
tions. This subgroup of patients (at low risk of deterioration) could be admitted without PIVC.
Therefore, we suggest an admitted cohort receive a CIPIVC when other indications will occur
as outlined in Table 3.
We expect our pragmatic A-PIVC decision aid will likely reduce the unwarranted idle PIVC
and likely support resource stewardship initiatives and perhaps facilitate appropriate vascular
access device placement. A-PIVC could better assist decisions for all ED staff to insert
CIPIVCs. The checking for the presence of an existing device or the use of alternative devices
for infusates that are likely to fail when infused via a PIVC can improve patient outcomes. As a
result it implements the concept of vessel health and preservation philosophy of the right
device for the right infusates at the right time, a valuable clinical notion [8,24–26]. This deci-
sion aid may appropriately decrease incidence of idle PIVCs and as a post insertion strategy as
it has the potential to guide decisions to remove PIVCs where no clinical indication exists.
Additionally, where the PIVC is the inappropriate VAD and therefore contributing to infu-
sion harm compromising vessel health and preservation, it suggests considering an alternative
VAD. However, decision tools or aids assisting with the identification of the appropriate VAD
selection and placement will require educational investment and resource planning. Such a
concept may yield greater outcomes for those admitted [8,20,27] and conceivably with a vascu-
lar access specialist team leading such an initiative [28].
Table 3. The A-PIVC decision aid to support CIPIVC use.
A Admission to hospital with the any of the following below
P Procedures requiring a PIVC (CT contrast scan); Check for the presence of an existing device but consider
whether this could be used rather than inserting a new PIVC.
I
V
Iv Fluids indicated where an equivalent cannot be tolerated enterally.
iV Medicines that cannot be tolerated enterally and are suitable for dilution in peripheral veins.
C Clinician predicts likelihood of use is over 80%.
https://doi.org/10.1371/journal.pone.0213923.t003
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The proportion of PIVCs inserted not associated with clinical utility such as a computerised
tomography contrast scan; evidence of intravenous fluids or medicines transfused; was 32%.
However, and perhaps, encouraging, is that our proportion of idle PIVCs is much less than
that reported by Limm and colleagues in another Australian ED (50%), [5] but similar to a sin-
gle centre retrospective ED study regarding the clinical utility of the PIVC [29].
Limitations
There are a number of limitations to our findings. Firstly, our sample is convenient and not
consecutive. Secondly, we could not accurately report if the PIVC was used for serial blood
sampling (particularly important in cardiac cases); additionally, we did not assess patient
choice/shared decision-making when PIVCs were inserted. Thirdly, when an ED PIVC was
inserted in someone with a pre-hospital PIVC we could not accurately identify which one was
used and if any were used for blood sampling, but results suggest preservation of veins or
reluctance to use an existing device is worthy of further exploration. Fourth, our data assessed
for all factors related to the device being used but we did not monitor if the patient was likely
to clinically deteriorate, and therefore some of the PIVCs may be justified as per local policy.
We did not assess what pre-registration; post-registration or what continuing education clini-
cians possessed or are available and whether this was associated with a CIPIVC insertion.
Finally, while having IV fluid or IV medication could be seen as clinically appropriate, we
highlight a limitation of reverse causation–meaning that fluid or medication was administered
because the patient had a PIVC or given IV antibiotics where oral may have sufficed. This
could have led to an underestimation of inappropriate PIVCs.
Conclusions
Prior to insertion a PIVC must be clinically indicated appropriate for the duration of patient
care. On the basis of our data and interpretation noting that external validation is required,
ED clinicians should simply ask does the patient they are caring for need A-PIVC by using our
novel decision aid. We hope A-PIVC will support a standard measurement for PIVC proce-
dures and when guided by local policy, driven by a clinical decision that, where possible,
includes the patient in the decision-making process. To our knowledge, this is one of the first
reports to develop a decision aid for a clinically indicated PIVC using a large prospective data-
set with a logistic regression technique. Future planned evaluation and validation studies of
A-PIVC are necessary and can address the limitations identified, but we believe that this sup-
ports other global Choosing Wisely initiatives on this topic. Finally, the A-PIVC aid could sup-
port purposeful clinician inertia on this topic. In the centuries since we have performed this
procedure it is past time that a decision regarding the insertion of a needle and plastic tube in a
person’s venous anatomy is clinically and ethically justified.
Supporting information
S1 Fig. When is a PIVC clinically indicated?
(PDF)
S2 Fig. The lifecycle of a PIVC.
(PDF)
Derivation of A-PIVC decision aid
PLOS ONE | https://doi.org/10.1371/journal.pone.0213923 March 22, 2019 11 / 14
Acknowledgments
The authors wish to thanks the patients who presented to the ED and allowed us to observe the
PIVC insertion. We are also extremely grateful to the clinicians of both SCGH and FSH who
consented to allow us to observe their procedure and are grateful to the hardworking-commit-
ted staff of both SCGH and FSH EDs. We are grateful to Ms. Shannon Nell RN who assisted
with observational data collection and Ms. Pip Bain and Ms. Lisa Douglas Smith CN for data
entry. We also acknowledge this work is supported by an academic support grant provided by
the Government of Western Australia, Department of Health, Nursing and Midwifery office.
Author Contributions
Conceptualization: Peter J. Carr.
Data curation: Peter J. Carr, James C. R. Rippey, Aileen Foale.
Formal analysis: Peter J. Carr, Marie L. Cooke, Michelle L. Trevenen, Claire M. Rickard.
Investigation: Peter J. Carr.
Methodology: Peter J. Carr, James C. R. Rippey, Marie L. Cooke, Michelle L. Trevenen, Claire
M. Rickard.
Project administration: Peter J. Carr, James C. R. Rippey, Aileen Foale, Claire M. Rickard.
Resources: Peter J. Carr, James C. R. Rippey, Marie L. Cooke, Niall S. Higgins, Michelle L. Tre-
venen, Claire M. Rickard.
Software: Michelle L. Trevenen.
Supervision: Marie L. Cooke, Niall S. Higgins, Claire M. Rickard.
Visualization: Michelle L. Trevenen, Gerben Keijzers, Claire M. Rickard.
Writing – original draft: Peter J. Carr.
Writing – review & editing: Peter J. Carr, James C. R. Rippey, Marie L. Cooke, Niall S. Hig-
gins, Michelle L. Trevenen, Aileen Foale, Gerben Keijzers, Claire M. Rickard.
References
1. Rivera AM, Strauss KW, Van Zundert A, Mortier E. The history of peripheral intravenous catheters: how
little plastic tubes revolutionized medicine. Acta Anaesthesiol Belg. AMB ACTA MEDICA BELGICA;
2005; 56: 271.
2. Sokol DK. “First do no harm” revisited. BMJ. 2013;347. https://doi.org/10.1136/bmj.f6426 PMID:
24163087
3. Alexandrou E, Ray-Barruel G, Carr PJ, Frost SA, Inwood S, Higgins N, et al. Use of Short Peripheral
Intravenous Catheters: Characteristics, Management, and Outcomes Worldwide. J Hosp Med.
2018;13. https://doi.org/10.12788/jhm.2923
4. Egerton-Warburton D, Ieraci S. First do no harm: In fact, first do nothing, at least not a cannula. Emerg
Med Australas. 2013; 25: 289–290. https://doi.org/10.1111/1742-6723.12109 PMID: 23911016
5. Limm EI, Fang X, Dendle C, Stuart RL, Egerton Warburton D. Half of All Peripheral Intravenous Lines in
an Australian Tertiary Emergency Department Are Unused: Pain With No Gain? Ann Emerg Med. 2013;
6. Go¨ransson KE, Johansson E. Indication and usage of peripheral venous catheters inserted in adult
patients during emergency care. J Vasc Access. 12: 193–9. Available: https://doi.org/10.5301/JVA.
2010.5967 PMID: 21058258
7. Carr PJ, Rippey JCR, Cooke ML, Higgins NS, Trevenen M, Foale A, et al. From insertion to removal: A
multicenter survival analysis of an admitted cohort with peripheral intravenous catheters inserted in the
emergency department. Infect Control Hosp Epidemiol. Cambridge University Press; 2018; 1–6. https://
doi.org/10.1017/ice.2018.190 PMID: 30196798
Derivation of A-PIVC decision aid
PLOS ONE | https://doi.org/10.1371/journal.pone.0213923 March 22, 2019 12 / 14
8. Moureau NL, Carr PJ. Vessel Health and Preservation: a model and clinical pathway for using vascular
access devices. Br J Nurs. MA Healthcare London; 2018; 27: S28–S35. https://doi.org/10.12968/bjon.
2018.27.8.S28 PMID: 29683752
9. Becerra MB, Shirley D, Safdar N. Prevalence, risk factors, and outcomes of idle intravenous catheters:
An integrative review. Am J Infect Control. 2016; https://doi.org/10.1016/j.ajic.2016.03.073 PMID:
27425008
10. Gledstone-Brown L, McHugh D. Review article: Idle ‘just-in-case’ peripheral intravenous cannulas in
the emergency department: Is something wrong? Emerg Med Australas. 2018; 30: 309–326. https://doi.
org/10.1111/1742-6723.12877 PMID: 29212137
11. Stuart RL, Cameron DR, Scott C, Kotsanas D, Grayson ML, Korman TM, et al. Peripheral intravenous
catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from
two tertiary health services. Med J Aust. 2013/06/04. 2013; 198: 551–553. https://doi.org/10.5694/
mja12.11699 PMID: 23725270
12. Carr PJ, Rippey JCR, Cooke ML, Bharat C, Murray K, Higgins NS, et al. Development of a clinical pre-
diction rule to improve peripheral intravenous cannulae first attempt success in the emergency depart-
ment and reduce post insertion failure rates: The vascular access decisions in the emergency room
(VADER) study protocol. BMJ Open. 2016; 6. https://doi.org/10.1136/bmjopen-2015-009196 PMID:
26868942
13. Marsh N, Mihala G, Ray-Barruel G, Webster J, Wallis MC, Rickard CM. Inter-rater agreement on PIVC-
associated phlebitis signs, symptoms and scales. J Eval Clin Pract. 2015; https://doi.org/10.1111/jep.
12396 PMID: 26183837
14. Carr PJ, Rippey J, Moore T, Ngo H, Cooke ML, Higgins NS, et al. Reasons for Removal of Emergency
Department-Inserted Peripheral Intravenous Cannulae in Admitted Patients: A Retrospective Medical
Chart Audit in Australia. Infect Control Hosp Epidemiol. 2016; 37. https://doi.org/10.1017/ice.2016.70
PMID: 27033301
15. Polit DF, Beck CT. The Content Validity Index: Are You Sure You Know What ‘ s Being Reported? Cri-
tique and Recommendations. 2006; 489–497. https://doi.org/10.1002/nur
16. McHugh ML. Interrater reliability: the kappa statistic. Biochem medica. 2012; 22: 276–82. Available:
http://www.ncbi.nlm.nih.gov/pubmed/23092060
17. R Core T. R: A language and environment for statistical computing. R Foundation for Statistical Com-
puting. [Internet]. Vienna, Austria; 2017. Available: http://www.r-project.org/
18. Marsh NR, Webster J, Larsen E, Cooke M, Mihala G, Rickard CM. Observational Study of Peripheral
Intravenous Catheter Outcomes in Adult Hospitalized Patients: A Multivariable Analysis of Peripheral
Intravenous Catheter Failure. https://doi.org/10.12788/jhm.2867 PMID: 29073316
19. Miliani K, Taravella R, Thillard D, Chauvin V, Martin E, Edouard S, et al. Peripheral Venous Catheter-
Related Adverse Events: Evaluation from a Multicentre Epidemiological Study in France (the CATHE-
VAL Project). Ma Z-L, editor. PLoS One. 2017; 12: e0168637. https://doi.org/10.1371/journal.pone.
0168637 PMID: 28045921
20. Chopra V, Flanders SA, Saint S, Woller SC, O’Grady NP, Safdar N, et al. The Michigan Appropriate-
ness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/
UCLA Appropriateness Method. Ann Intern Med. American College of Physicians; 2015; 163: S1.
https://doi.org/10.7326/M15-0744 PMID: 26369828
21. Kelly A-M, Egerton-Warburton D. When is peripheral intravenous catheter insertion indicated in the
emergency department? Emerg Med Australas. 2014; 26: 515–6. https://doi.org/10.1111/1742-6723.
12282 PMID: 25186163
22. Hawkins T, Greenslade JH, Suna J, Williams J, Jensen M, Donohue M, et al. Peripheral Intravenous
Cannula Insertion and Use in the Emergency Department; an Intervention Study. Acad Emerg Med.
2017; https://doi.org/10.1111/acem.13335 PMID: 29044739
23. Rippey JC, Carr PJ, Cooke M, Higgins N, Rickard CM. Predicting and preventing peripheral intravenous
cannula insertion failure in the emergency department: Clinician ‘gestalt’ wins again. Emerg Med Aus-
tralas. Wiley Publishing Asia Pty Ltd; 2016; https://doi.org/10.1111/1742-6723.12695 PMID: 27862989
24. Moureau N, Trick N, Nifong T, Perry C, Kelley C, Carrico R, et al. Vessel health and preservation (Part
1): a new evidence-based approach to vascular access selection and management. J Vasc Access.
2012/02/07. 2012; 13: 351–356. https://doi.org/10.5301/jva.5000042 PMID: 22307471
25. Hallam C, Weston V, Denton A, Hill S, Bodenham A, Dunn H, et al. Development of the UK Vessel
Health and Preservation (VHP) framework: a multi-organisational collaborative. J Infect Prev. 2016;
1757177415624752-. https://doi.org/10.1177/1757177415624752 PMID: 28989456
26. Jackson T, Hallam C, Corner T, Hill S. Right line, right patient, right time: Every choice matters. Br J
Nurs. 2013; 22: S24–S28. https://doi.org/10.12968/bjon.2013.22.Sup5.S24 PMID: 23752501
Derivation of A-PIVC decision aid
PLOS ONE | https://doi.org/10.1371/journal.pone.0213923 March 22, 2019 13 / 14
27. Barton AJ, Danek G, Johns P, Coons M. Improving patient outcomes through CQI: vascular access
planning. J Nurs Care Qual. UNITED STATES; 1998; 13: 77–85. https://doi.org/10.1097/00001786-
199812000-00010 PMID: 9842178
28. Carr PJ, Higgins NS, Cooke ML, Mihala G, Rickard CM. Vascular access specialist teams for device
insertion and prevention of failure. Cochrane Database Syst Rev. 2018; 3: CD011429. https://doi.org/
10.1002/14651858.CD011429.pub2 PMID: 29558570
29. Fry M, Romero B, Berry A. Utility of peripheral intravenous cannulae inserted in one tertiary referral
emergency department: A medical record audit. Australas Emerg Nurs J. 2016; 19: 20–25. https://doi.
org/10.1016/j.aenj.2015.10.003 PMID: 26718065
Derivation of A-PIVC decision aid
PLOS ONE | https://doi.org/10.1371/journal.pone.0213923 March 22, 2019 14 / 14
